Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Cardium Provides Update On Phase 2b Excellarate Clinical Study And Plans For Additional Tissue Repair Applications
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled study, has enrolled 124 diabetic patients with non-healing, lower extremity neuropathic ulcers.
generic viagra online
Sen. McConnell Says Filibuster Of Supreme Court Nominee Sotomayor Remains Possible
Appearing on CBS" "Face the Nation" on Sunday, Senate Minority Leader Mitch McConnel (R-Ky.) said that Senate Republicans have not ruled out a filibuster on the Supreme Court nomination of Judge Sonia Sotomayor, The Hill reports. Although McConnell acknowledged that he has "consistently opposed filibustering judges," he added that the "precedent was established" when Democrats filibustered Miguel Estrada, an appeals court nominee under former President George W. Bush. When asked to clarify his statement, McConnell added, "The Democrats have firmly established that as a precedent, but that doesn"t mean you are going to use it" (Blake, The Hill, 6/14). McConnell also said that it is "way too early to be talking about whether or not anybody opposes this nominee" (Schieffer, "Face the Nation," CBS, 6/14).According to The Hill, McConnell is the first top GOP senator to state that a filibuster is a possibility, as most other Republicans have said only that it is too early to determine if it should be an option. Republicans "face a difficult path" if they choose to filibuster Sotomayor because party members have long decried judicial filibusters, The Hill reports (The Hill, 6/14).
News of the day
Embryo Movement Stimulates Joint Formation
A new study uncovers a molecular mechanism that explains why joints fail to develop in embryos with paralyzed limbs. The research, published by Cell Press in the May issue of the journal Developmental Cell, answers a longstanding question about the influence of muscle activity on developing joints and underscores the critical contribution of movement to regulation of a signaling pathway that is important during development and beyond.
Endocrinology

Dr. David Fischell To Speak At The EuroPCR Conference In Barcelona On The Detection Of Plaque Rupture With The AngelMed Guardian System.

Angel Medical Systems has announced that Dr. David Fischell, Chief Executive Officer, will be the first featured speaker at the upcoming Out-of-the-box "Session Innovation@EuroPCR09" on May 19 in Barcelona, Spain. EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Dr. Fischell"s presentation will highlight data from recent human clinical studies showing the AngelMed Guardian System"s ability to detect vulnerable plaque rupture. "When someone has a heart attack, it is typically the result of a blood clot closing one of the three major coronary arteries. When this happens, there is a shift in the ST segment of the heart signal caused by the electrical difference between the portion of the heart muscle fed by the closed artery and the rest of the heart that is still receiving oxygen," says Dr. Fischell. The Guardian System is designed to internally monitor ECG signals in real time, 24-hours-a-day, to detect these ST shifts resulting from coronary occlusions. The System is comprised of an internal implantable device about the size of a pacemaker with a single pacemaker lead into the heart, an external pager-like alerting device, and a programmer that lets physicians read out the heart signals. Early clinical cases have shown the Guardian System"s ability to detect plaque ruptures in patients and warn them to seek immediate medical attention. "Experimental and clinical studies have shown that most of the damage to the heart occurs during the first two hours after coronary occlusion," adds Dr. Fischell. "This device has the potential to warn patients hours--perhaps even days--before a heart attack occurs." The Guardian System is currently available commercially in Brazil, and is in the ALERTS Phase II Pivotal trial in clinical sites across the United States. The first implants in the ALERTS trial took place in December, 2008 with sites across more than 10 states now enrolling patients in the study. Angel Medical is currently ISO 13485 certified and is working with a notified body to gain CE mark approval. Angel Medical Systems


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009